Marco Trovo1, Davide Franceschini2, Carlo Furlan3, Francesca Pietrobon3, Stefano Vagge4, Eleonora Farina5, Alberto Revelant5, Luca Visani6, Virginia Maragna6, Giuseppe Parisi7, Vieri Scotti6. 1. Department of Radiation Oncology, Azienda Sanitaria Universitaria Integrata Udine, P.le Santa Maria della Misericordia 15, 33100, Udine, Italy. 2. Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital, Rozzano, Via Manzoni 56, Rozzano, Milan, Italy. 3. Department of Radiation Oncology, Ospedale San Martino di Belluno, Viale Europa 22, 32100, Belluno, Italy. 4. Department of Radiation Oncology, Azienda Ospedaliera Universitaria San Martino di Genova - IST, Istituto Nazionale Ricerca sul Cancro, Largo Rosanna Benzi, 10, 16132, Genoa, Italy. 5. Radiation Oncology Department, National Cancer Institute, CRO IRCCS, Via Franco Gallini, 2, 33081, Aviano, PN, Italy. 6. Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy. 7. Department of Radiation Oncology, Azienda Sanitaria Universitaria Integrata Udine, P.le Santa Maria della Misericordia 15, 33100, Udine, Italy. giuseppe.parisi@asuiud.sanita.fvg.it.
Abstract
PURPOSE: To assess the outcome of malignant pleural mesothelioma patients treated with extra-pleural pneumonectomy (EPP) and adjuvant radiotherapy (RT), using the most advanced radiotherapeutic techniques, namely image-guided intensity-modulated RT (IG-IMRT). METHODS AND MATERIALS: Fifty-four patients were analyzed. Minimum radiation dose was 50 Gy (2 Gy/fr). Planning target volume encompassed the entire hemithorax, including the ipsilateral mediastinum if interested by disease, the pericardium and diaphragm, and any drain sites. The study endpoints included loco-regional control (LRC), distant metastases free survival (DMFS), and overall survival (OS), as well as radiation-related toxicity. RESULTS: Major patients and treatment characteristics were the following: median age 62 years, epithelioid histology in 51 (94%) cases, locally advanced disease in 41 (90%) cases, and metastatic mediastinal lymph nodes in 27 patients (50%). Only 7 patients (13%) had gross residual disease after surgery. Chemotherapy was administered in 38 patients (70%). Median follow-up was 16 months (range 0-73 months). Median and 2-year OS were 21 months and was 43.8%, respectively. The predominant pattern of failure was distant: 34 patients (62.9%) developed some component of distant failure, and only 5 patients (9.2%) developed an isolated loco-regional recurrence. The estimates of LRC and DMFS at 2 years were 63.4% and 43.4%, respectively. Three fatal pneumonitis were documented. Other major toxicities included: Grade 2 and 3 pneumonitis in 1 and 2 cases, respectively, 1 case of bronchial fistula, pleural empyema, and Grade 3 esophagitis, respectively. CONCLUSIONS: Although executed in the era of high-technology radiotherapy (IG-IMRT), EPP should not be routinely performed.
PURPOSE: To assess the outcome of malignant pleural mesotheliomapatients treated with extra-pleural pneumonectomy (EPP) and adjuvant radiotherapy (RT), using the most advanced radiotherapeutic techniques, namely image-guided intensity-modulated RT (IG-IMRT). METHODS AND MATERIALS: Fifty-four patients were analyzed. Minimum radiation dose was 50 Gy (2 Gy/fr). Planning target volume encompassed the entire hemithorax, including the ipsilateral mediastinum if interested by disease, the pericardium and diaphragm, and any drain sites. The study endpoints included loco-regional control (LRC), distant metastases free survival (DMFS), and overall survival (OS), as well as radiation-related toxicity. RESULTS: Major patients and treatment characteristics were the following: median age 62 years, epithelioid histology in 51 (94%) cases, locally advanced disease in 41 (90%) cases, and metastatic mediastinal lymph nodes in 27 patients (50%). Only 7 patients (13%) had gross residual disease after surgery. Chemotherapy was administered in 38 patients (70%). Median follow-up was 16 months (range 0-73 months). Median and 2-year OS were 21 months and was 43.8%, respectively. The predominant pattern of failure was distant: 34 patients (62.9%) developed some component of distant failure, and only 5 patients (9.2%) developed an isolated loco-regional recurrence. The estimates of LRC and DMFS at 2 years were 63.4% and 43.4%, respectively. Three fatal pneumonitis were documented. Other major toxicities included: Grade 2 and 3 pneumonitis in 1 and 2 cases, respectively, 1 case of bronchial fistula, pleural empyema, and Grade 3 esophagitis, respectively. CONCLUSIONS: Although executed in the era of high-technology radiotherapy (IG-IMRT), EPP should not be routinely performed.
Authors: Philippe Giraud; Alma Sylvestre; Sofia Zefkili; Albert Lisbona; Pierre Bonnette; Françoise Le Pimpec Barthes; Edouard Paris; Christian Perigaud; Alexia Savignoni; Marc-André Mahé Journal: Radiother Oncol Date: 2011-08-22 Impact factor: 6.280
Authors: Pretesh R Patel; Sua Yoo; Gloria Broadwater; Lawrence B Marks; Edward F Miles; Thomas A D'Amico; David Harpole; Chris R Kelsey Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-01 Impact factor: 7.038
Authors: Kenneth M Forster; W Roy Smythe; George Starkschall; Zhongxing Liao; Tsuyoshi Takanaka; Jason F Kelly; Ara Vaporciyan; Anesa Ahamad; Lei Dong; Mohammad Salehpour; Ritsuko Komaki; Craig W Stevens Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-01 Impact factor: 7.038
Authors: Anesa Ahamad; Craig W Stevens; W Roy Smythe; Ara A Vaporciyan; Ritsuko Komaki; Jason F Kelly; Zhongxing Liao; George Starkschall; Kenneth M Forster Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-01 Impact factor: 7.038
Authors: Marc de Perrot; Ronald Feld; B C John Cho; Andrea Bezjak; Masaki Anraku; Ronald Burkes; Heidi Roberts; Ming S Tsao; Natasha Leighl; Shaf Keshavjee; Michael R Johnston Journal: J Clin Oncol Date: 2009-02-17 Impact factor: 44.544
Authors: Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209
Authors: Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto Journal: Lancet Oncol Date: 2011-06-30 Impact factor: 41.316